INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by INVO Bioscience, Inc. on March 31, 2022. The filing serves to announce the company's financial results for the fiscal year ended December 31, 2021, and to provide an update on the status of its INVO Centers. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC under the symbol "INVO."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No specific material changes in financial condition or operations are detailed in the text of this 8-K. The document acts as a conduit to the full year 2021 results and a strategic presentation regarding INVO Centers.
Guidance, Outlook, and Management Commentary
- Financial Results: The company issued a press release on March 31, 2022, detailing results for the year ended December 31, 2021.
- Operational Update: Exhibit 99.2 contains a presentation titled "INVO Center Review-March 2022," which discusses the current status of existing INVO Centers and plans for establishing additional centers.
- Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2021 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 for details on the expansion timeline and operational capacity of new INVO Centers.
- Verify the company's liquidity status and runway based on the full financial statements referenced in the press release.
- Confirm any updates to the company's strategic roadmap for fertility treatment services.